Paul Lountzis
Lountzis Asset Management
Paul Lountzis Novo Nordisk A/S stake
total: 139
Lountzis Asset Management NVO trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2020 Q2
- Held for:
- 3 quarters
- Latest activity:
- 2021 Q1
According to 2026 Q2 report, Paul Lountzis doesn't hold any Novo Nordisk A/S (NVO) shares. To date, the estimated cost basis is nearly $69.23 for "buy" trades and estimated average "sell" price is $69.23. Lountzis Asset Management first purchased NVO in 2020 Q2, initially acquiring 130 shares. Since the initial investment in Novo Nordisk A/S (NVO), Lountzis Asset Management has made 1 more transaction.
When did Paul Lountzis sell Novo Nordisk A/S (NVO)?
Paul Lountzis sold off the entire Novo Nordisk A/S (NVO) position in 2021 Q1.
When did Paul Lountzis buy Novo Nordisk A/S (NVO)?
Paul Lountzis first invested in Novo Nordisk A/S (NVO) in 2020 Q2 at the reported quarter-end price of $69.23 per share.
What's the cost basis of Lountzis Asset Management's NVO stake?
The estimated cost basis for Novo Nordisk A/S (NVO) stake is around $69.23 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $69.23
- Weighted AVG sell price:
- $69.23
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.